Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130746 | 0.87 | — | — | |
| SCHEMBL131272 | 0.80 | — | — | |
| SCHEMBL23790310 | 0.79 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL941164 | 0.77 | OPRM1 (0.35) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL13623179 | 0.77 | OPRM1 (0.35) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2292865 | 0.75 | — | — | |
| SCHEMBL17616410 | 0.75 | — | — | |
| SCHEMBL2295003 | 0.75 | — | — | |
| SCHEMBL20221293 | 0.74 | — | — | |
| SCHEMBL18268918 | 0.73 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230024012-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | THE SCRIPPS RESEARCH INSTITUTE | 2023-01-26 | — | — | US | disclosed |
| US-10800780-B2 | TDO2 Inhibitors | GENENTECH, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190016726-A1 | TDO2 Inhibitors | PHARMARON BEIJING CO. LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| US-9931324-B2 | Indolizine derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2018-04-03 | — | — | US | disclosed |
| US-9931324-B2 | Indolizine derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2018-04-03 | — | — | US | disclosed |
| WO-2017107979-A1 | TDO2 INHIBITORS | GENENTECH, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170079965-A1 | NOVEL INDOLIZINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| US-9546166-B2 | Indolizine derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2017-01-17 | — | — | US | disclosed |
| US-20160031879-A1 | NOVEL INDOLIZINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024012-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | ACE, ACE2, TMPRSS2 | OPRM1 1835/4885OPRD1 1315/4885OPRK1 1623/4885 |
| US-20190016726-A1 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | OPRM1 1597/4885OPRD1 967/4885OPRK1 996/4885 |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | OPRM1 626/4885OPRD1 1518/4885OPRK1 2051/4885 |
| US-20170079965-A1 | NOVEL INDOLIZINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX5, P2RX4, P2RX3 | OPRM1 533/4885OPRD1 654/4885OPRK1 308/4885 |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | ACE, ACE2, TMPRSS2 | OPRM1 1835/4885OPRD1 1315/4885OPRK1 1623/4885 |
| US-20160031879-A1 | NOVEL INDOLIZINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX5, P2RX4, P2RX3 | OPRM1 533/4885OPRD1 654/4885OPRK1 308/4885 |
| US-10800780-B2 | TDO2 Inhibitors | TDO2, IDO2, IDO1 | OPRM1 1597/4885OPRD1 967/4885OPRK1 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.